In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the trials and data surrounding antibody-drug conjugate (ADC) treatment for patients with Hodgkin lymphoma (HL). Dr Collins begins by highlighting the survival benefits associated with brentuximab vedotin in various settings, citing the results of the AETHERA (NCT01100502) and ECHELON-1 (NCT01712490) trials. Following this, Dr Collins sheds light on the toxicities and remission rates associated with the ADC camidanlumab tesirine (Cami). This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.